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Hunting Down the Responsible Cells, But Then What?*Megan Monsanto, BS, Mark A. Sussman, PHDA ctivated cardiac ﬁbroblasts (CFs) play a crit-ical role in remodeling the heart followingmyocardial infarction (MI) but a clear con-
sensus on the origin and biological properties of these
dynamic cells remains elusive. In this issue of the
Journal, Ruiz-Villalba et al. (1) endeavor to resolve
the origin of CFs participating in tissue repair
following MI by cell lineage tracing of 2 different sus-
pected sources.SEE PAGE 2057In general, the consensus is that CFs are recruited
by endothelial cells via endothelial-mesenchymal
transition (EndMT) or from the bone marrow; it also
has been proposed that both resident CFs and
migrating pericytes may be additional sources of
ﬁbroblast in the wake of cardiac damage (2–6).
Indeed, the authors report that an undifferentiated
epicardium-derived cell (EPDC) gives rise to CFs
following injury in their model. Expansion and
differentiation of EPDCs is secondary to an acute
inﬂammatory response of inﬁltrating bone marrow–
derived blood cells (BMCs) at the site of injury. Acti-
vated CFs mobilize and interact with BMCs, triggering
cell polarization and matrix deposition contributing
to scar formation. Ruiz-Villalba et al. (1) highlighted
the clinical importance of elucidating mechanisms of*Editorials published in the Journal of the American College of Cardiology
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views of JACC or the American College of Cardiology.
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Inc.post-MI ventricular remodeling with the hope of both
providing a strategy to control cardiac ﬁbrosis and
modulating an environment favorable to cell-based
therapies.
The adult mammalian heart has limited regenera-
tive capacity, leading to loss of cardiomyocytes dur-
ing acute infarction. Data from several studies (7–9)
suggest that such factors as hypoxia, reactive oxygen
species, and a cytokine-rich environment activate
ﬁbroblasts following MI. Characterization of CFs has
been hampered by the lack of a robust CF-speciﬁc
molecular marker and the cell population’s hetero-
geneity. Tracking of the CF origin in this study was
accomplished by lineage tracing to examine the
contribution of BMCs and EPDCs to CF formation
after MI. However, the study stops short of examining
the possibility that CFs may originate from endo-
thelial cells via EndMT, an important point because
both EndMT and bone marrow–derived ﬁbroblasts
within the myocardium have been associated with
pathological remodeling. Additional studies with
previously documented transgenic Tie2-Cre or VE-
cadherin-Cre transgenic mouse lines would have
helped resolve the possible endothelial origin of CFs.
Epicardial cells that line the surface of the heart
were tracked using Cre/loxP transgenic mice to
identify cells expressing Wilm’s Tumor Gene 1 (Wt1),
a transcriptional regulator that plays a key role in
heart development and epicardial epithelial to
mesenchymal transition (EMT) (10). The transgenic
approach allows for Wt1þ cells to be permanently
labeled with enhanced yellow ﬂuorescent protein
(eYFP). Immunoﬂuorescence revealed eYFP/Wt1þ
cells localized at the epicardium at embryonic day (E)
10, and through EMT gave rise to the EPDCs. At E11.5,
eYFPþ EPDCs were the ﬁrst cells to transition and
occupy the myocardial interstitial space, completing
the homing process between E15.5 and birth and
remaining interstitial post-natally (Figure 1). Caveats
FIGURE 1 Origin of Cardiac Fibroblasts
Current opinion is that most cardiac ﬁbroblasts originate from the bone marrow, endothelium, and/or the epicardium following myocardial infarction (MI). The study
performed by Ruiz-Villalba et al. (1) identiﬁes epicardium-derived cells (EPDCs) as the main source of cardiac ﬁbroblasts following acute infarction. At embryonic day
(E) 15.5, epithelial cells lining the epicardium migrate to the myocardial interstitial space. The undifferentiated EPDCs become activated cardiac ﬁbroblasts upon
myocardial injury.
Monsanto and Sussman J A C C V O L . 6 5 , N O . 1 9 , 2 0 1 5
Myocardial Infarct Scar M A Y 1 9 , 2 0 1 5 : 2 0 6 7 – 9
2068when interpreting results from fate mapping studies
using the murine Cre/loxP recombinase approach
include variable sensitivity of the system, or lack
thereof, depending on the reporter (10,11), but fate
mapping remains the cutting-edge approach until
real-time imaging to track individual cell movement
is possible on live animals.
The possibility of a circulating BMC origin for CFs
as previously suggested (4) was addressed by Ruiz-
Villalba et al. (1) by tracing BMC cardiac homing
after monomeric red ﬂuorescent protein (mRFP) bone
marrow transplantation into irradiated recipient
mice. BMC contribution to the cardiac interstitium
was found to be very low (<2% of nonmyocardial
cells) and therefore does not seem to be the major
source of CFs in the healthy adult heart. Subse-
quently, after showing negligible BMC inﬁltration
into the normal undamaged myocardium, mRFPþ
BMCs were transplanted into Wt1Cre-eYFPþ mice
subjected to ligation of the left anterior descending
coronary artery to induce MI. Contribution of EPDCs
and BMCs in the context of ventricular remodeling
was assessed at multiple time points after injury.
As expected, extensive myocardial cell death was
observed concurrent with an increase in circulating
mRFPþ BMCs in the infarct zone (IZ) following left
anterior descending coronary artery ligation. Expan-
sion of resident epicardium-derived CFs follows BMC
inﬁltration into the IZ, with the number of EPDCs
steadily increasing to match that of the BMCs at the
1-week time point (mRFP/eYFP cell ratio, 0.97  0.18).The authors demonstrated that migratory homing of
EPDCs occurs in response to the myocardially
secreted chemokine stromal cell-derived factor 1a.
Interestingly, they found that EPDC and BMC com-
pose 90.2  2.1% of total cells present in the IZ.
Spatially, both cell types are tightly packed and
polarized with the long axes of CFs and BMCs running
parallel to one another.
Characterization of the interstitial EPDC revealed a
population of CD90þ/CD31/smooth muscle actin,
type alow cells that when sorted from infarcted hearts,
showed at least a partial population with CF-like
qualities including high levels of collagen I tran-
script. In contrast, CD45þ sorted BMCs showed nearly
undetectable levels of collagen I messenger ribonu-
cleic acid, reinforcing the conclusion that ﬁbroblast
origin is not from the bone marrow.
To verify that the CFs differentiate from resident
interstitial EPDCs and not from adult epicardium EMT
reactivation, the authors checked for expression of
classic epicardial markers, such as Wt1 and Raldh2, in
the eYFPþ subepicardial cell population. Signiﬁcant
expression of epicardial markers was not seen in the
interstitial space of the subepicardium at any stage
examined in this study, conﬁrming that the adult
epicardium is not the source of newly formed CFs.
In summary, Ruiz-Villalba et al. (1) conclude
interstitial EPDCs are the main source of CFs in the
ischemic heart and that patterned collagen deposi-
tion in the post-MI ﬁbrotic scar depends on interac-
tion of BMCs with the epicardium-derived CFs.
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2069Speculatively, the authors assert that saturation of
BMCs and EPDCs at the site of injury prevents
efﬁcient engraftment of injected stem/progenitor
cells, but this remains a hypothetical possibility
without basis and requires longitudinal time course
studies following injury to truly assess the question
of donated cell engraftment. Indeed, many studies
with adoptive transfer of stem cells following injury
report signiﬁcantly reduced scar formation and
collagen deposition. Thus, although the study by
Ruiz-Villalba et al. brings the ﬁeld a step closer to
understanding the cellular origins of cardiac ﬁbrosis,
the authors do not explore potential routes of mini-
mizing malignant scarring to improve cell-based
therapies. Drugs that target ﬁbrotic proteins, such as
transforming growth factor-b and platelet-derived
growth factor, are currently being considered as
antiﬁbrotic treatments (12).
However, it remains to be seen if identifying EPDCs
as the primary origin of CFs in the ischemic contextwill be of notable clinical relevance for future
development of antiﬁbrotic drugs. Although target-
ing the cellular source of EPDC-derived CFs is one
possibility, it would need to be determined whether
other cell populations would compensate for the loss
of a select cell type in the heart and, equally
important, whether short-term scar reduction in the
wake of MI has long-term deleterious consequences
for repair, remodeling, and functional competency of
the heart. In the end, although the contribution of
EPDC is appreciable in the context of this study, the
debate about how to best deal with ﬁbroblasts in
the injured myocardium will undoubtedly continue
for years to come.
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